Recent insights into anti-tumor immunotherapy have led to a wave of clinical trials involving
immunotherapy for lung cancer. Vaccines have evolved from nonspecific immune
stimulants, like Bacillus Calmette-Guerin (BCG), to much more specific and potent strategies,
some of which generate active immune responses against tumor-associated antigens.
Understanding the mechanisms of anti-tumor immunity and identifying target antigens will
likely improve these therapeutic strategies and provide them with a niche in the future of …